Verrica Pharmaceuticals Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $1.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $150.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $4.00K, a 42.86% decline year-over-year.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $7.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $155.00K, a 2114.29% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $7.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $558.00K, a 23.18% increase from fiscal 2020.
- Verrica Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $453.00K, a 7.09% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $155.00K 10-K · filed 2026-03-11 | |
| 2024-09-30 | $1.00K 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $150.00K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $4.00K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $7.00K 10-K · filed 2025-03-11 | |
| 2023-03-31 | $7.00K 10-Q · filed 2024-11-05 | |
| 2021-12-31 | $558.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $45.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $277.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $240.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $453.00K 10-K · filed 2022-03-02 | |
| 2020-03-31 | $7.00K 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $423.00K 10-K · filed 2021-03-17 | |
| 2019-09-30 | $4.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $212.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $3.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $7.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |